Table 1 The regulation of YAP/TAZ activity by GPCR-associated signaling in human malignancies
From: YAP and endothelin-1 signaling: an emerging alliance in cancer
GPCRs | Coupling Protein | Cancer Type | Drugs | References |
|---|---|---|---|---|
LPA receptors | Gα12/13 Gαq/11 | Ovarian cancer | Phosphatase-resistant LPA analogues Monoclonal antibodies for LPA | |
S1P receptors | Gα12/13 | Ovarian cancer, Hepatocellular carcinoma | Monoclonal antibodies for S1P | |
G protein-coupled estrogen receptor (GPER) | Gαq/11 | Breast cancer | GPER inhibitors (agonist analogous, G15) | [74] |
Protease-activated receptors (PARs) | Gα12/13 Gαq/11 | Breast cancer | RhoA GTPase inhibitors (C3 transferase) | |
Melanoma | ||||
Colon cancer | ||||
Lung cancer | ||||
Pancreatic cancer | ||||
Prostate cancer | ||||
Squamous cell carcinoma of the head and neck | ||||
Angiotensin II Receptor (AT1) | Gαq/11 | Prostate cancer | Angiotensin receptor blockers (losartan) | |
Cholangiocarcinoma | ||||
Prostaglandin E2 receptor (EP2) | Gαq/11 | Colon cancer | Prostaglandin synthetase blockers (indomethacin) | |
Hepatocellular carcinoma | ||||
Head and neck cancer | ||||
Non-small cell lung cancer | ||||
Chemochine (C-X-C motif) receptor 4 (CXCR4) | Gα12/13 Gαq/11 | Non-small cell lung cancer | CXCR4 antagonists (WZ811) | [81] |
Breast cancer | ||||
Oral squamous carcinoma | ||||
Chronic Myelogenous leukemia | ||||
Free Fatty Acid receptor 1 (FFAR1) | Gαq/11 | Prostate cancer | Docosahexaenoic acid (DHA) | [82] |
Wnt receptor (Frizzled, FRD) | Gα12/13 | Colorectal cancer | RhoA GTPase inhibitors (C3 transferase) | [83] |
Prostate cancer | ||||
Hepatocellular carcinoma | ||||
Endothelin A receptor (ETAR) | Gαq/11 | Colon cancer | Selective ETAR antagonists (BQ123) | [87] |
Endothelin A receptor (ETAR) | β-arr1 | Ovarian cancer | Dual ET-1R antagonists (macitentan) | |
Breast cancer |